Amitriptyline Hydrochloride and Denileukin Diftitox

• Generic Name: amitriptyline
• Dosage Forms: n.a.
• Other Brand Names: Vanatrip, Elavil, Endep

Management of major depressive disorder.

Has been used in fixed combination with chlordiazepoxide in the management of depression associated with moderate to severe anxiety.

Management of moderate to severe anxiety and/or agitation (in fixed combination with perphenazine) in patients with depressed mood.

Management of severe anxiety and/or agitation (in fixed combination with perphenazine) in patients with depression.

Management of depression and anxiety (in fixed combination with perphenazine) in association with chronic physical disease.

Management of acute depressive episodes (in fixed combination with perphenazine) in patients with schizophrenia.

Second-line agent in attention deficit hyperactivity disorder (ADHD) patients unable to tolerate or unresponsive to stimulants; should be used only under close supervision.

Associated with a narrower margin of safety than some other therapeutic agents; use only if clearly indicated and with careful monitoring, including baseline and subsequent determinations of ECG and other parameters.

Medium to high efficacy for prophylaxis of migraine headache.

Equivocal efficacy for management of eating disorders (e.g., bulimia, anorexia nervosa); avoid use in underweight individuals and in those exhibiting suicidal ideation.

Has been used for the short-term management of acute depressive episodes in bipolar disorder.

TCAs associated with a greater risk of precipitating hypomania or manic episodes than other classes of antidepressants; should always be used in combination with a mood stabilizer (e.g., lithium).

Among the drugs of choice for the symptomatic treatment of postherpetic neuralgia.

Less effective for insomnia and associated with more serious adverse reactions than conventional hypnotics.

• Generic Name: denileukin diftitox
• Dosage Forms: n.a.
• Other Brand Names: Ontak

Treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) in patients whose malignant cells express the CD25 component of the IL-2 receptor (designated an orphan drug by FDA for this use).

Safety and efficacy in patients with CTCL whose malignant cells do not express the CD25 component of the IL-2 receptor not established but currently being studied.